Beraud E, Golstein M M, Viallet F, Sela B A, Galibert R, Durbec J P, Khalil R, Gastaut J L, Richard P, Roux H
Laboratoire d'Immunopathologie, Faculté de Médecine, Marseille.
Autoimmunity. 1990;6(1-2):13-21. doi: 10.3109/08916939008993366.
Cell-mediated immunity (CMI) to myelin components has been implicated in Multiple Sclerosis (MS) pathogenesis: two targets were suggested, Myelin Basic Protein with controversial results and, more recently, gangliosides. In order to investigate their possible involvement, we have performed Leukocyte Migration inhibition (LMI) tests in the presence of human brain gangliosides. Thirty nine MS patients (twenty four being "definite", according to McDonald and Halliday's classification), twenty nine patients with Other Neurological Diseases (OND), thirty six patients with Inflammatory diseases (ID) and forty healthy controls were tested. MS patients were divided into two groups, depending on the clinical stage of the disease. The mean migration inhibition percentage of the MS-attack group was found to be significantly different from the four others (p less than 0.01) (24.4 +/- 16.2 versus 10.9 +/- 8.5 in MS without attack, 4.4 +/- 12.9 in OND, 3.9 +/- 13.9 in ID and 11.1 +/- 12.1 in healthy subjects). LMI to gangliosides is therefore significantly increased during the attack stage in MS. These results support the notion of a Delayed Type Hypersensitivity to these glycolipids during the active stage of the disease.
细胞介导的针对髓鞘成分的免疫反应已被认为与多发性硬化症（MS）的发病机制有关：有两个靶点被提出，髓鞘碱性蛋白（结果存在争议）以及最近提出的神经节苷脂。为了研究它们可能的参与情况，我们在人脑神经节苷脂存在的情况下进行了白细胞迁移抑制（LMI）试验。对39例MS患者（根据麦克唐纳和哈利迪的分类，其中24例为“确诊”）、29例患有其他神经系统疾病（OND）的患者、36例患有炎症性疾病（ID）的患者以及40名健康对照者进行了测试。MS患者根据疾病的临床阶段分为两组。发现MS发作组的平均迁移抑制百分比与其他四组有显著差异（p小于0.01）（发作期MS患者为24.4±16.2，非发作期MS患者为10.9±8.5，OND患者为4.4±12.9，ID患者为3.9±13.9，健康受试者为11.1±12.1）。因此，在MS发作期，对神经节苷脂的LMI显著增加。这些结果支持了在疾病活动期对这些糖脂存在迟发型超敏反应的观点。
